Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine
- PMID: 19690307
- DOI: 10.1001/jama.2009.1201
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine
Abstract
Context: In June 2006, the Food and Drug Administration licensed the quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccine (qHPV) in the United States for use in females aged 9 to 26 years; the Advisory Committee on Immunization Practices then recommended qHPV for routine vaccination of girls aged 11 to 12 years.
Objective: To summarize reports to the Vaccine Adverse Event Reporting System (VAERS) following receipt of qHPV.
Design, setting, and participants: Review and describe adverse events following immunization (AEFIs) reported to VAERS, a national, voluntary, passive surveillance system, from June 1, 2006, through December 31, 2008. Additional analyses were performed for some AEFIs in prelicensure trials, those of unusual severity, or those that had received public attention. Statistical data mining, including proportional reporting ratios (PRRs) and empirical Bayesian geometric mean methods, were used to detect disproportionality in reporting.
Main outcome measures: Numbers of reported AEFIs, reporting rates (reports per 100,000 doses of distributed vaccine or per person-years at risk), and comparisons with expected background rates.
Results: VAERS received 12 424 reports of AEFIs following qHPV distribution, a rate of 53.9 reports per 100,000 doses distributed. A total of 772 reports (6.2% of all reports) described serious AEFIs, including 32 reports of death. The reporting rates per 100,000 qHPV doses distributed were 8.2 for syncope; 7.5 for local site reactions; 6.8 for dizziness; 5.0 for nausea; 4.1 for headache; 3.1 for hypersensitivity reactions; 2.6 for urticaria; 0.2 for venous thromboembolic events, autoimmune disorders, and Guillain-Barré syndrome; 0.1 for anaphylaxis and death; 0.04 for transverse myelitis and pancreatitis; and 0.009 for motor neuron disease. Disproportional reporting of syncope and venous thromboembolic events was noted with data mining methods.
Conclusions: Most of the AEFI rates were not greater than the background rates compared with other vaccines, but there was disproportional reporting of syncope and venous thromboembolic events. The significance of these findings must be tempered with the limitations (possible underreporting) of a passive reporting system.
Comment in
-
The risks and benefits of HPV vaccination.JAMA. 2009 Aug 19;302(7):795-6. doi: 10.1001/jama.2009.1215. JAMA. 2009. PMID: 19690315 No abstract available.
-
Adverse events and quadrivalent human papillomavirus recombinant vaccine.JAMA. 2009 Dec 23;302(24):2657; author reply 2657-8. doi: 10.1001/jama.2009.1880. JAMA. 2009. PMID: 20040547 No abstract available.
Similar articles
-
Safety of the 9-Valent Human Papillomavirus Vaccine.Pediatrics. 2019 Dec;144(6):e20191791. doi: 10.1542/peds.2019-1791. Epub 2019 Nov 18. Pediatrics. 2019. PMID: 31740500 Free PMC article.
-
Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.Vaccine. 2018 Mar 20;36(13):1781-1788. doi: 10.1016/j.vaccine.2018.02.034. Epub 2018 Feb 21. Vaccine. 2018. PMID: 29477308
-
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.Pediatr Infect Dis J. 2015 Sep;34(9):983-91. doi: 10.1097/INF.0000000000000793. Pediatr Infect Dis J. 2015. PMID: 26107345 Review.
-
Allergic reactions to Japanese encephalitis vaccine.Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. doi: 10.1016/s0889-8561(03)00102-4. Immunol Allergy Clin North Am. 2003. PMID: 14753386 Review.
-
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543
Cited by
-
Real-world data of China: Analysis of HPV vaccine coverage and post-vaccination adverse reaction monitoring in Western Chinese provinces from 2018 to 2021.Hum Vaccin Immunother. 2024 Dec 31;20(1):2315653. doi: 10.1080/21645515.2024.2315653. Epub 2024 Feb 19. Hum Vaccin Immunother. 2024. PMID: 38372046 Free PMC article.
-
Incidence of Adolescent Syncope and Related Injuries Following Vaccination and Routine Venipuncture.J Adolesc Health. 2024 Apr;74(4):696-702. doi: 10.1016/j.jadohealth.2023.11.005. Epub 2023 Dec 9. J Adolesc Health. 2024. PMID: 38069938
-
Ocular Inflammation Post-Vaccination.Vaccines (Basel). 2023 Oct 23;11(10):1626. doi: 10.3390/vaccines11101626. Vaccines (Basel). 2023. PMID: 37897028 Free PMC article. Review.
-
Evidence supporting the initiation of HPV vaccination starting at age 9: Collection overview.Hum Vaccin Immunother. 2023 Dec 15;19(3):2269026. doi: 10.1080/21645515.2023.2269026. Epub 2023 Oct 12. Hum Vaccin Immunother. 2023. PMID: 37824444 Free PMC article. No abstract available.
-
Factors Associated with College Students' Human Papillomavirus (HPV) Vaccination and Preferred Strategies for Catch-Up Vaccine Promotion: A Mixed-Methods Study.Vaccines (Basel). 2023 Jun 20;11(6):1124. doi: 10.3390/vaccines11061124. Vaccines (Basel). 2023. PMID: 37376513 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources